Core Viewpoint - Karolinska Development AB emphasizes its clear strategy and stable scientific foundation for its investment portfolio, focusing on patient benefits amidst challenging market conditions [1]. Significant Events - Organon plans to discontinue the clinical development of drug candidate OG-6219, following Phase 2 study results [3]. - Umecrine Cognition presented preclinical data on golexanolone's effects on Parkinsonian symptoms at the AD/PD 2025 conference [4]. - Umecrine Cognition received a USD 420,000 research grant from The Michael J. Fox Foundation for golexanolone studies [4]. - OssDsign achieved a milestone of treating 10,000 patients with its bone graft product in the US market [4]. - Karolinska Development divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million [4]. Financial Update - The net profit/loss for Q2 2025 was SEK -73.3 million, compared to SEK -16.0 million in Q2 2024 [5]. - The total fair value of the portfolio decreased to SEK 1,384.9 million at the end of June 2025, down from SEK 1,434.2 million [5]. - Net asset value at the end of June 2025 was SEK 1,148.6 million, or SEK 4.3 per share, compared to SEK 1,238.2 million, or SEK 4.6 per share, at the end of June 2024 [5]. - Cash and cash equivalents increased by SEK 20.0 million, totaling SEK 71.1 million on June 30, 2025 [5].

STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully carried out a unit issue, provid ...

Core Insights - Modus Therapeutics has successfully completed patient enrollment for part 1 of its clinical phase 2a study evaluating sevuparin as a treatment for chronic kidney disease with anemia [1][2] - The study aims to assess the safety and dosing levels of sevuparin in patients with chronic kidney disease (stage 3-5) and healthy volunteers, conducted in Italy [2] - Karolinska Development holds a 66% ownership stake in Modus Therapeutics, indicating significant investment in the company's potential [3] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [4][5] - The company aims to build companies around leading scientists and experienced management teams, co-funded by international investors to enhance the likelihood of success [5][6] - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by a strong global network [6]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].